Arcutis Biotherapeutics (ARQT) Other Operating Expenses (2022 - 2026)

Arcutis Biotherapeutics' Other Operating Expenses history runs 5 years deep, the most recent figure standing at $9.8 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 10.8% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $37.6 million (up 52.41% YoY), while the FY2025 annual figure was $36.7 million, up 91.84% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $9.8 million, down from $11.7 million in the prior quarter.
• The five-year high for Other Operating Expenses was $40.4 million in Q3 2022, with the low at $485000.0 in Q4 2022.
• The 5-year median for Other Operating Expenses is $5.5 million (2024), against an average of $7.4 million.
• The sharpest annual moves came in 2023 and 2024: Other Operating Expenses plunged 97.07% in 2023, then jumped 365.57% in 2024.
• Arcutis Biotherapeutics' Other Operating Expenses stood at $485000.0 in 2022, then jumped by 363.09% to $2.2 million in 2023, then jumped by 207.44% to $6.9 million in 2024, then jumped by 69.27% to $11.7 million in 2025, then fell by 16.29% to $9.8 million in 2026.
• Business Quant data shows ARQT's Other Operating Expenses at $9.8 million in Q1 2026, $11.7 million in Q4 2025, and $8.7 million in Q3 2025.